Skip to content

Study · Systematic review · 2020

10 results

Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.

Dimitrios P, Michael D, Vasilios K, Konstantinos S, Konstantinos I, Ioanna Z, Konstantinos P, Spyridon B, Asterios K

Current diabetes reviews1 Jan 2020Cited by 39 (Europe PMC)

PMID31203802 (opens in a new tab)DOI10.2174/1573399815666190614141918 (opens in a new tab)PepBankPUB-31203802
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with type 1 diabetes on insulin, adding liraglutide gave modest reductions in HbA1c, greatest with 1.8 mg.

    In plain wordsIn people with type 1 diabetes on insulin, adding liraglutide lowered HbA1c a little, most with 1.8 mg.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    MD
    −0.24%
    liraglutide 1.8 mg

    Source sentences

    Summary
    Liraglutide provided modest reductions in HbA1c, with liraglutide 1.8 mg producing the greatest decrease (MD = -0.24%, 95% CI -0.32 to -0.16, I2=0%).
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with type 1 diabetes on insulin, adding liraglutide significantly reduced body weight, by up to 4.87 kg with 1.8 mg.

    In plain wordsIn people with type 1 diabetes on insulin, adding liraglutide reduced body weight, by up to 4.87 kg with 1.8 mg.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    Weight reduction (maximum)
    4.87 kg
    liraglutide 1.8 mg

    Source sentences

    Summary
    Significant weight reduction, up to 4.87 kg with liraglutide 1.8 mg was also observed (95% CI -5.31 to -4.43, I2=0%).
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with type 1 diabetes on insulin, adding liraglutide decreased the total daily insulin dose.

    In plain wordsIn people with type 1 diabetes, adding liraglutide lowered the amount of insulin needed each day.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal daily insulin dose
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Decrease in total daily insulin dose, primarily driven by a decrease in bolus insulin requirements, was demonstrated.
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with type 1 diabetes on insulin, adding liraglutide decreased bolus insulin requirements.

    In plain wordsIn people with type 1 diabetes, adding liraglutide lowered the mealtime (bolus) insulin needed.

    Peptide
    Liraglutide
    Outcome
    DecreaseBolus insulin requirement
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Decrease in total daily insulin dose, primarily driven by a decrease in bolus insulin requirements, was demonstrated.
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  5. 05HumanSystematic reviewSafety outcome

    In patients with type 1 diabetes on insulin, liraglutide non-significantly decreased the odds of severe hypoglycemia.

    In plain wordsIn people with type 1 diabetes, adding liraglutide did not significantly change the odds of severe low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere hypoglycemia
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    OR
    0.8 NA
    severe hypoglycemia

    Source sentences

    Summary
    Liraglutide decreased non-significantly the odds for severe hypoglycemia (OR=0.80, 95% CI 0.57-1.14, I2=0%)
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  6. 06HumanSystematic reviewSafety outcome

    In patients with type 1 diabetes on insulin, liraglutide significantly increased the odds of nausea.

    In plain wordsIn people with type 1 diabetes, adding liraglutide made nausea more likely.

    Peptide
    Liraglutide
    Outcome
    IncreaseNausea
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    4.7 NA
    nausea

    Source sentences

    Summary
    for nausea, OR=4.70, 95% CI 3.68-6.00, I2=37%
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  7. 07HumanSystematic reviewSafety outcome

    In patients with type 1 diabetes on insulin, liraglutide significantly increased the odds of vomiting.

    In plain wordsIn people with type 1 diabetes, adding liraglutide made vomiting more likely.

    Peptide
    Liraglutide
    Outcome
    IncreaseVomiting
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    2.5 NA
    vomiting

    Source sentences

    Summary
    for vomiting, OR=2.50, 95% CI 1.54-4.72, I2=27%
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  8. 08HumanSystematic reviewSafety outcome

    In patients with type 1 diabetes on insulin, liraglutide significantly increased heart rate.

    In plain wordsIn people with type 1 diabetes, adding liraglutide raised heart rate.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A significant increase in heart rate was also demonstrated.
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  9. 09HumanSystematic reviewSafety outcome

    In patients with type 1 diabetes on insulin, no association of liraglutide with diabetic ketoacidosis was identified.

    In plain wordsIn people with type 1 diabetes, no link between liraglutide and diabetic ketoacidosis was found.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiabetic ketoacidosis
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No association with diabetic ketoacidosis or malignancies was identified.
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.
  10. 10HumanSystematic reviewSafety outcome

    In patients with type 1 diabetes on insulin, no association of liraglutide with malignancies was identified.

    In plain wordsIn people with type 1 diabetes, no link between liraglutide and cancers was found.

    Peptide
    Liraglutide
    Outcome
    No significant changeMalignancies
    Study

    n: not reported in source

    Comparator
    Placebo or any other comparator
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No association with diabetic ketoacidosis or malignancies was identified.
    2 context sentences
    Summary · context
    We searched major databases and grey literature from their inception to October 2018, for RCTs with a duration ≥ 12 weeks, comparing liraglutide with placebo or any other comparator as adjunct to insulin in patients with T1D, investigating major efficacy and safety endpoints.
    Summary · context
    We included 5 trials with 2,445 randomized participants.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.